Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases

Mamdouhi, Tania; Twomey, Julianne D.; McSweeney, K. Melodi; Zhang, Baolin

doi:10.1007/s10555-019-09795-4

Cited by 25 publications

(20 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the CellSearch system depends on EpCAM and since EpCAM is not expressed in all nmBC tissues [24] or EpCAM expression may be lowered or lost during epithelial-tomesenchymal transition [25,26], many alternative assays have been developed (an in-depth overview in the study of Mamdouhi et al [27]). However, generally, the prognostic value of CTC assays alternative to CellSearch has been more or less anecdotal and less rigorous than that of CellSearch.…”

Section: Ctc Detection Using Other Systemsmentioning

confidence: 99%

Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Kruijff

Beije

Martens

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

Section: Ctc Detection Using Other Systemsmentioning

confidence: 99%

Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Kruijff

Beije

Martens

et al. 2021

European Urology Oncology

View full text Add to dashboard Cite

“…Based on the “seed and soil” theory, a small portion of CTCs (<0.01%) may seed a secondary tumor (metastasis) . Clinical evidence has demonstrated the presence of CTCs in various metastatic carcinomas (e.g., melanoma, breast, and prostate) . It has also been reported that CTCs can be used for studying protein localization and cell morphology of tumor cells, which cannot be provided by other liquid biopsy biomarkers .…”

Section: Plasmonic Nanomaterial‐based Sers Liquid Biopsy Analysesmentioning

confidence: 99%

Engineering State‐of‐the‐Art Plasmonic Nanomaterials for SERS‐Based Clinical Liquid Biopsy Applications

et al. 2019

View full text Add to dashboard Cite

Precision oncology, defined as the use of the molecular understanding of cancer to implement personalized patient treatment, is currently at the heart of revolutionizing oncology practice. Due to the need for repeated molecular tumor analyses in facilitating precision oncology, liquid biopsies, which involve the detection of noninvasive cancer biomarkers in circulation, may be a critical key. Yet, existing liquid biopsy analysis technologies are still undergoing an evolution to address the challenges of analyzing trace quantities of circulating tumor biomarkers reliably and cost effectively. Consequently, the recent emergence of cutting-edge plasmonic nanomaterials represents a paradigm shift in harnessing the unique merits of surface-enhanced Raman scattering (SERS) biosensing platforms for clinical liquid biopsy applications. Herein, an expansive review on the design/synthesis of a new generation of diverse plasmonic nanomaterials, and an updated evaluation of their demonstrated SERS-based uses in liquid biopsies, such as circulating tumor cells, tumor-derived extracellular vesicles, as well as circulating cancer proteins, and tumor nucleic acids is presented. Existing challenges impeding the clinical translation of plasmonic nanomaterials for SERS-based liquid biopsy applications are also identified, and outlooks and insights into advancing this rapidly growing field for practical patient use are provided.

show abstract

“…Potential challenges may include low amounts of CTCs and ctDNA in samples, lack of pre-analytical and analytical consensus, clinical validation, regulatory endorsement and cost effectiveness [ 97 , 98 ]. Currently, the use of CTCs in routine diagnostics is limited, mainly due to methodological constraints, such as the lack of an established assessment practice, beyond enumeration [ 99 , 100 ]. The epithelial cell adhesion molecule (EpCAM)-dependent technique was approved by the U.S. Food and Drug Administration (FDA) in 2004, and represents the “gold standard” for CTC isolation in different cancers, including CRC [ 101 ].…”

Section: Current Issues and Limitations Of Liquid Biopsymentioning

confidence: 99%

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

et al. 2020

View full text Add to dashboard Cite

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high specificity and sensitivity in patients with colorectal cancer. A “liquid biopsy” is characterized by the isolation of cancer-derived components, such as circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs, and proteins, from peripheral blood or other body fluids and their genomic or proteomic assessment. The liquid biopsy is a minimally invasive and repeatable technique that could play a significant role in screening and diagnosis, and predict relapse and metastasis, as well as monitoring minimal residual disease and chemotherapy resistance in colorectal cancer patients. However, there are still some practical issues that need to be addressed before liquid biopsy can be widely used in clinical practice. Potential challenges may include low amounts of circulating tumor cells and circulating tumor DNA in samples, lack of pre-analytical and analytical consensus, clinical validation, and regulatory endorsement. The aim of this review was to summarize the current knowledge of the role of liquid biopsy in the management of colorectal cancer.

show abstract

Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases

Cited by 25 publications

References 51 publications

Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Liquid Biopsies to Select Patients for Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: A Systematic Review

Engineering State‐of‐the‐Art Plasmonic Nanomaterials for SERS‐Based Clinical Liquid Biopsy Applications

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

Contact Info

Product

Resources

About